Medical Condition News

RSS

Eplerenone reduces new onset atrial fibrillation and flutter in patients with class 2 heart failure

The aldosterone antagonist eplerenone significantly reduced the development of new onset atrial fibrillation and flutter in patients with class 2 heart failure, concludes a sub-analysis of the EMPHASIS-HF trial, presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology.

23 May 2011

Paralyzed man walks again

Three years ago, baseball champion Rob Summers was hit by a speeding car in Portland, Oregon which smashed into his legs and left him with appalling injuries. He was told he would spend the rest of his life in a wheelchair at best. However the 25 year old has become the first person paralyzed from the chest down to stand and take a step unaided.

22 May 2011

UB's graded exercise test for concussion could help decide hockey player's fitness to return to the ice

As the chase for the 2011 Stanley Cup heads to the finish, several players are off the ice suffering from concussion, an injury all too common in this contact sport.

21 May 2011

NIH allocated $400 million funding for pain research in 2010

An unprecedented level of federal funding for pain research, some $400 million, was allocated in 2010 by the National Institutes of Health (NIH) through provisions of the American Recovery and Investment Act and the Affordable Care Act to help accelerate advances in pain research, prevention and treatment.

21 May 2011

Salk researchers successfully edit diseased gene in patient-specific induced pluripotent stem cells

In principle, genetic engineering is simple, but in practice, replacing a faulty gene with a healthy copy is anything but. Using mutated versions of the lamin A gene as an example to demonstrate the versatility of their virus-based approach, researchers at the Salk Institute for Biological Studies successfully edited a diseased gene in patient-specific induced pluripotent stem cells as well as adult stem cells.

21 May 2011

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Eli Lilly and Company announced Phase I data on LY2127399, a human monoclonal antibody that neutralizes B-cell activating factor (BAFF), for use in combination with bortezomib in patients with previously-treated multiple myeloma.

21 May 2011

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

Although chemotherapy is used to kill cancer cells, it can also have a strong toxic effect on normal cells such as bone marrow and blood cells, often limiting the ability to use and manage the chemotherapy treatment.

21 May 2011

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent

A pooled analysis of the global RESOLUTE clinical program presented today during a late-breaking clinical trials session at EuroPCR demonstrated the strong safety record of the Resolute drug-eluting stent (DES) from Medtronic, Inc., across a wide variety of patient and lesion types.

From Medtronic 21 May 2011

Wills Eye Institute and Thomas Jefferson University create new vision research center

A new vision research center based in Philadelphia will foster regional, national and global collaborations among a diverse group of exceptional clinicians and researchers working to better diagnose, treat and prevent visual diseases.

21 May 2011

FDA approves SUTENT for treatment of pancreatic NET

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.

21 May 2011

Electrical experiment helps paralyzed man stand, walk

An electrode experiment has helped a paralyzed man stand and walk for short periods, which has some calling it a major breakthrough in treating paralysis. In other news, Ford is developing health-monitoring technology for cars.

21 May 2011

Medicine, osteopathy, physical therapy and chiropractic colleges collaborate to study safety in spinal manipulation

A recent team grant by the Canadian Institute for Health Research is providing an innovative approach to researching patient safety for those who provide and receive spinal-manipulative therapy. The $2-million grant over five years brings together health researchers from across Canada and will involve input from four regulatory colleges in Alberta.

21 May 2011

APS honors recipients of Clinical Centers of Excellence in Pain Management Awards

The American Pain Society, www.ampainsoc.org, today honored the recipients of its fifth annual Clinical Centers of Excellence in Pain Management Awards recognizing the nation's outstanding pain care centers.

21 May 2011

Some cancer patients go without drugs because of high cost

New targeted pills can have dramatic effects on cancer, not only driving the disease into remission but also freeing patients from hours of uncomfortable and boring chemotherapy treatments. Up to 10 percent of patients, however, are not filling their prescriptions for the pills--and cost appears to be a factor, according to a new report.

21 May 2011

Study shows why individuals with anorexia nervosa have paradoxical response to food

Perhaps the most puzzling symptom of anorexia nervosa - a disorder that tends to occur in young women - is the refusal to eat, resulting in extreme weight loss. While most people have a great deal of difficulty in dieting and losing weight, particularly if a diet extends over many months or years, individuals with anorexia nervosa can literally diet themselves to death. In fact, this disorder has a very high death rate from starvation.

21 May 2011

New study raises doubts about benefits of ezetimibe in patients suffering from high LDL cholesterol

More than 42 million Americans suffer from high cholesterol, and 63 million more have borderline high cholesterol. Over time, high levels of LDL cholesterol, often called "bad cholesterol," build up along the walls of arteries and blood vessels, a process called atherosclerosis, which can lead to a high risk of heart disease, stroke and heart attack.

21 May 2011

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Salix Pharmaceuticals, Ltd. today announced findings from two analyses of a Phase 3 open-label study of RELISTOR (methylnaltrexone bromide) presented at the 30th Annual Scientific Meeting of the American Pain Society. The meeting is being held in Austin, TX, on May 19-21, 2011.

21 May 2011

Researchers uncover new details of unusual biological mechanism in brains of diverse species

Researchers at the University of California, San Diego School of Medicine have uncovered new details of an unusual biological mechanism in the brains of diverse species that not only helps regulate how their brains develop, but also how they function later in life. The discovery could lead to new biomarkers for specific neurological diseases in humans and, possibly, the development of drugs to cure them.

21 May 2011

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

Patch angioplasty improves post-exercise ABI's and reduces reoperation rates in competitive cyclists

Results from a midterm study of highly competitive cyclists who underwent external iliac artery reconstruction (AR) and inguinal ligament release (LR) were reported today at the 65th Vascular Annual Meeting® presented by the Society for Vascular Surgery (SVS).

21 May 2011

Medical Condition News

Eplerenone reduces new onset atrial fibrillation and flutter in patients with class 2 heart failure

Paralyzed man walks again

UB's graded exercise test for concussion could help decide hockey player's fitness to return to the ice

NIH allocated $400 million funding for pain research in 2010

Salk researchers successfully edit diseased gene in patient-specific induced pluripotent stem cells

Lilly Phase I multiple myeloma study affirms potential of LY2127399-bortezomib combination

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent

Wills Eye Institute and Thomas Jefferson University create new vision research center

FDA approves SUTENT for treatment of pancreatic NET

Electrical experiment helps paralyzed man stand, walk

Medicine, osteopathy, physical therapy and chiropractic colleges collaborate to study safety in spinal manipulation

APS honors recipients of Clinical Centers of Excellence in Pain Management Awards

Some cancer patients go without drugs because of high cost

Study shows why individuals with anorexia nervosa have paradoxical response to food

New study raises doubts about benefits of ezetimibe in patients suffering from high LDL cholesterol

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Researchers uncover new details of unusual biological mechanism in brains of diverse species

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Patch angioplasty improves post-exercise ABI's and reduces reoperation rates in competitive cyclists

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Latest News